Gerd Fastner1, Cornelia Hauser-Kronberger2, Angelika Moder3, Roland Reitsamer4,5, Franz Zehentmayr6, Peter Kopp6, Christoph Fussl6, Thorsten Fischer4,5, Heinrich Deutschmann6,7, Felix Sedlmayer6. 1. Department of Radiotherapy and Radio-Oncology, Landeskrankenhaus, Paracelsus Medical University, Muellner Hauptstrasse 48, 5020, Salzburg, Austria. g.fastner@salk.at. 2. Department of Pathology, Landeskrankenhaus, Paracelsus Medical University, Salzburg, Austria. 3. Institute of Inborn Errors in Metabolism, Landeskrankenhaus, Paracelsus Medical University, Salzburg, Austria. 4. Department of Special Gynecology, Landeskrankenhaus, Paracelsus Medical University, Salzburg, Austria. 5. Department of Gynecology, Landeskrankenhaus, Paracelsus Medical University, Salzburg, Austria. 6. Department of Radiotherapy and Radio-Oncology, Landeskrankenhaus, Paracelsus Medical University, Muellner Hauptstrasse 48, 5020, Salzburg, Austria. 7. Institute for Research and Development of Advanced Radiation Technologies (radART), Paracelsus Medical University, Salzburg, Austria.
Abstract
AIM: The purpose of this work was to retrospectively evaluate survival and local control rates of triple-negative breast cancer subtypes classified as five marker negative (5NP) and core basal (CB), respectively, after breast-conserving surgery and intraoperative boost radiotherapy with electrons (IOERT) followed by whole breast irradiation. METHODS AND MATERIALS: A total of 71 patients with triple-negative breast cancer were enrolled, who were treated with lumpectomy, axillary lymph node dissection, and IOERT with 9.6 Gy (median Dmax) followed by normofractionated whole breast irradiation to median total doses of 54 Gy. Chemotherapy was applied in a neoadjuvant (12 %), adjuvant (75 %), or combinational setting (7 %). RESULTS: After a median follow-up of 97 months (range 4-170 months), 5 in-breast recurrences were detected (7.0 %). For all patients, 8-year actuarial rates for local control, metastases-free survival, disease-specific survival, and overall survival amounted to 89, 75, 80, and 69 %, respectively. All local recurrences occurred in grade 3 (G3) tumors irrespective of their specific immunohistochemical phenotype; thus, the local control rate for grades 1/2 (G1/2) was 100 % for both 5NP and CB, while for G3 it was 88 % for 5NP and 90 % for CB (p = 0.65 and 0.82, respectively, n.s.). For disease-specific survival, only the difference of the best-prognosis group 5-NP/G3 vs. the worst-prognosis cohort CB/G1/2 was statistically significant: 90 % vs. 54 % (p = 0.03). CONCLUSION: Boost-IOERT provides acceptable long-term in-breast control in triple negative breast cancer. The best subgroup in terms of disease-specific survival was represented by 5NP in combination with tumor grading G3.
AIM: The purpose of this work was to retrospectively evaluate survival and local control rates of triple-negative breast cancer subtypes classified as five marker negative (5NP) and core basal (CB), respectively, after breast-conserving surgery and intraoperative boost radiotherapy with electrons (IOERT) followed by whole breast irradiation. METHODS AND MATERIALS: A total of 71 patients with triple-negative breast cancer were enrolled, who were treated with lumpectomy, axillary lymph node dissection, and IOERT with 9.6 Gy (median Dmax) followed by normofractionated whole breast irradiation to median total doses of 54 Gy. Chemotherapy was applied in a neoadjuvant (12 %), adjuvant (75 %), or combinational setting (7 %). RESULTS: After a median follow-up of 97 months (range 4-170 months), 5 in-breast recurrences were detected (7.0 %). For all patients, 8-year actuarial rates for local control, metastases-free survival, disease-specific survival, and overall survival amounted to 89, 75, 80, and 69 %, respectively. All local recurrences occurred in grade 3 (G3) tumors irrespective of their specific immunohistochemical phenotype; thus, the local control rate for grades 1/2 (G1/2) was 100 % for both 5NP and CB, while for G3 it was 88 % for 5NP and 90 % for CB (p = 0.65 and 0.82, respectively, n.s.). For disease-specific survival, only the difference of the best-prognosis group 5-NP/G3 vs. the worst-prognosis cohort CB/G1/2 was statistically significant: 90 % vs. 54 % (p = 0.03). CONCLUSION: Boost-IOERT provides acceptable long-term in-breast control in triple negative breast cancer. The best subgroup in terms of disease-specific survival was represented by 5NP in combination with tumor grading G3.
Entities:
Keywords:
Breast conserving surgery; Electrons; Intraoperative radiotherapy; Recurrence; Triple-negative breast neoplasms
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Zeinab Elsawaf; Hans-Peter Sinn; Joachim Rom; Justo Lorenzo Bermejo; Andreas Schneeweiss; Sebastian Aulmann Journal: Breast Date: 2013-06-24 Impact factor: 4.380
Authors: Sandra S Zaky; Maryjo Lund; Kelly A May; Karen D Godette; Jonathan J Beitler; Leslie R Holmes; Ruth M O'Regan; Esther S Yu; David S Yu; Jerome C Landry Journal: Ann Surg Oncol Date: 2011-03-26 Impact factor: 5.344
Authors: Roland Reitsamer; Felix Sedlmayer; Michael Kopp; Gerhard Kametriser; Christian Menzel; Heinz Deutschmann; Olaf Nairz; Wolfgang Hitzl; Florentia Peintinger Journal: Int J Cancer Date: 2006-06-01 Impact factor: 7.396
Authors: Barbara Belletti; Jayant S Vaidya; Sara D'Andrea; Frank Entschladen; Mario Roncadin; Francesca Lovat; Stefania Berton; Tiziana Perin; Ezio Candiani; Sonia Reccanello; Andrea Veronesi; Vincenzo Canzonieri; Mauro G Trovò; Kurt S Zaenker; Alfonso Colombatti; Gustavo Baldassarre; Samuele Massarut Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: M Krengli; F A Calvo; F Sedlmayer; C V Sole; G Fastner; M Alessandro; S Maluta; R Corvò; E Sperk; M Litoborski; C Pisani; C Fillini; F Fusconi; M F Osti; L Tomio; H Marsiglia; A Ciabattoni; W Polkowski; A Di Grazia; A Gava; A Kuten; C Iotti; C Gonzalez; M Sallabanda; J-B Dubois; G Catalano; V Valentini Journal: Strahlenther Onkol Date: 2013-07-12 Impact factor: 3.621
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976
Authors: G Oses; C Cases; I Valduvieco; B Farrús; I Alonso; X Caparrós; J Mases; D Muñoz-Guglielmetti; A Biete; C Castro; E Escudero; M Molina; A Herreros; J Saez; M Mollà Journal: Clin Transl Oncol Date: 2021-02-03 Impact factor: 3.405
Authors: Julia Kaiser; Roland Reitsamer; Peter Kopp; Christoph Gaisberger; Michael Kopp; Thorsten Fischer; Franz Zehentmayr; Felix Sedlmayer; Gerd Fastner Journal: Breast Care (Basel) Date: 2018-05-30 Impact factor: 2.860
Authors: Hans-Christian Kolberg; György Lövey; Leyla Akpolat-Basci; Miltiades Stephanou; Peter Fasching; Michael Untch; Oliver Hoffmann; Max Bulsara; Jayant Vaidya; Cornelia Liedtke Journal: Breast Care (Basel) Date: 2017-09-21 Impact factor: 2.860
Authors: Felix Sedlmayer; Roland Reitsamer; Frederik Wenz; Elena Sperk; Christoph Fussl; Julia Kaiser; Ingrid Ziegler; Franz Zehentmayr; Heinz Deutschmann; Peter Kopp; Gerd Fastner Journal: Radiat Oncol Date: 2017-01-19 Impact factor: 3.481
Authors: Wolfgang Harms; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; D Krug; M D Piroth; M-L Sautter-Bihl; F Sedlmayer; R Souchon; F Wenz; R Sauer Journal: Strahlenther Onkol Date: 2016-03-01 Impact factor: 3.621
Authors: Shelly Wen; Lucy Manuel; Moira Doolan; Justin Westhuyzen; Thomas P Shakespeare; Noel J Aherne Journal: Breast Cancer (Dove Med Press) Date: 2020-03-06
Authors: Raluca Stoian; Thalia Erbes; Constantinos Zamboglou; Jutta Scholber; Mark Gainey; Ilias Sachpazidis; Erik Haehl; Simon K B Spohn; Vivek Verma; David Krug; Alexander Rühle; Ingolf Juhasz-Böss; Anca-Ligia Grosu; Nils H Nicolay; Tanja Sprave Journal: Strahlenther Onkol Date: 2021-04-30 Impact factor: 3.621